Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report for 2022, highlighting revenues of RMB 43.952 billion (USD 6.381 billion), marking a 12.66% increase year-on-year (YOY). The company’s net profits also saw a significant rise, reaching RMB 3.873 billion (USD 562.4 million), up 18.17% YOY.
Emphasis on Innovative Research and Development
During the year, Fosun Pharma intensified its focus on innovative research and development (R&D). The company’s investment in pharmaceutical R&D reached RMB 5.097 billion (USD 740.1 million), a 13.62% increase YOY. R&D expenditure stood at RMB 3.552 billion (USD 515.76 million), representing 11.53% of the pharmaceutical business income. The year 2022 was marked by the approval of six in-house developed novel drugs, four in-licensed novel drugs, and 27 generic drugs in the Chinese mainland, Hong Kong, and the US. Additionally, seven novel drugs and 30 generic drugs were filed for marketing in China, with 22 novel drugs obtaining clinical trial approvals.
Contribution of Key Products to Revenues
The combined sales of key products such as HanLiKang, Zercepac, BNT162b2, azvudine, Doptelet, and serplulimab accounted for more than 30% of Fosun Pharma’s revenues. This highlights the strong performance and market acceptance of these products.
Global Revenues and Strategic Partnerships
Fosun Pharma generated RMB 13.938 billion (USD 2.023 billion) in revenues from regions and countries outside of mainland China, contributing to 31.71% of the company’s operational income. The company secured a licensing deal with Amgen for Otezla (apremilast) and parsabiv. Subsidiary Henlius Pharma entered into licensing agreements with Getz Pharma, Eurofarma, Abbott, Organon, and others. Another unit, Gland Pharma, acquired Cenexi, a European-based contract development and manufacturing organization (CDMO). Fosun Pharma is also advancing the market launch of HanSiZhuang and generics in the United States and has established self-operating sales teams in Africa and India through Tridem Pharma and Gland Pharma, respectively.-Fineline Info & Tech
